|
| 36462470 | The nine hole peg test as an outcome measure in progressive MS trials. | Mult Scler Relat Disord | 2023 |
| 37830451 | Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset. | Mult Scler | 2023 |
| 37173129 | Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis. | J Neurol Neurosurg Psychiatry | 2023 |
| 37306560 | Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis. | Eur J Neurol | 2023 |
| 37072219 | Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset. | Neurology | 2023 |
| 37461624 | Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies <i>LRRC4C, LHX5-AS1</i> and nominates ancestry-specific loci <i>PTPRK</i> , <i>GRB14</i> , and <i>KIAA0825</i> as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium. | medRxiv | 2023 |
| 36513155 | Diabetic Retinopathy and Dementia Association, Beyond Diabetes Severity. | Am J Ophthalmol | 2023 |
| 34304609 | MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. | Mult Scler | 2022 |
| 35496758 | A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. | Mult Scler J Exp Transl Clin | 2022 |
| 35570237 | The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. | J Neurol | 2022 |
| 35876467 | The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials. | Mult Scler | 2022 |
| 35211872 | Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study. | Adv Ther | 2022 |
| 34965774 | Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. | Mult Scler | 2022 |
| 34870676 | Association Between Cataract Extraction and Development of Dementia. | JAMA Intern Med | 2022 |
| 34927308 | Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis. | Eur J Neurol | 2022 |
| 34647974 | Association of Performance on Dichotic Auditory Tests With Risk for Incident Dementia and Alzheimer Dementia. | JAMA Otolaryngol Head Neck Surg | 2022 |
| 34392376 | Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. | J Neurol | 2022 |
| 33448539 | Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis? | Eur J Neurol | 2021 |
| 33900044 | Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. | Alzheimers Dement | 2021 |
| 33749651 | Associations Between Retinal Artery/Vein Occlusions and Risk of Vascular Dementia. | J Alzheimers Dis | 2021 |
| 33554906 | Glucose-Dementia Association Is Consistent Over Blood Pressure/Antihypertensive Groups. | J Alzheimers Dis | 2021 |
| 33578191 | Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. | Mult Scler Relat Disord | 2021 |
| 34284316 | Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. | Mult Scler Relat Disord | 2021 |
| 33106389 | Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. | Neurology | 2021 |
| 32457226 | COVID-19 in MS: Initial observations from the Pacific Northwest. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 32436028 | Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. | Adv Ther | 2020 |
| 32202612 | Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. | JAMA Neurol | 2020 |
| 30820047 | Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. | Nat Genet | 2019 |
| 30098888 | Associations between recent and established ophthalmic conditions and risk of Alzheimer's disease. | Alzheimers Dement | 2019 |
| 31256124 | Associations Between Depression, Traumatic Brain Injury, and Cognitively-Defined Late-Onset Alzheimer's Disease Subgroups. | J Alzheimers Dis | 2019 |
| 30893465 | Reply to: Comment on: Serum Cholesterol and Incident Alzheimer's Disease: Findings From the Adult Changes in Thought Study. | J Am Geriatr Soc | 2019 |
| 30794930 | Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. | Biol Blood Marrow Transplant | 2019 |
| 31162312 | Highly Aggressive Multiple Sclerosis. | Continuum (Minneap Minn) | 2019 |
| 30909213 | Using Varying Diagnostic Criteria to Examine Mild Cognitive Impairment Prevalence and Predict Dementia Incidence in a Community-Based Sample. | J Alzheimers Dis | 2019 |
| 29439122 | Iron-Insensitive Quantitative Assessment of Subcortical Gray Matter Demyelination in Multiple Sclerosis Using the Macromolecular Proton Fraction. | AJNR Am J Neuroradiol | 2018 |
| 30574342 | A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. | Mult Scler J Exp Transl Clin | 2018 |
| 30289959 | Serum Cholesterol and Incident Alzheimer's Disease: Findings from the Adult Changes in Thought Study. | J Am Geriatr Soc | 2018 |
| 28714976 | Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. | Nat Genet | 2017 |
| 28222301 | Impact of home visit capacity on genetic association studies of late-onset Alzheimer's disease. | Alzheimers Dement | 2017 |
| 28131217 | Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis. | J Neurol Sci | 2017 |
| 28326883 | Oral rather than intravenous corticosteroids should be used to treat MS relapses - No. | Mult Scler | 2017 |
| 28241268 | Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. | JAMA Neurol | 2017 |
| 28148635 | High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. | Neurology | 2017 |
| 28940184 | Cognitive Trajectory Changes Over 20 Years Before Dementia Diagnosis: A Large Cohort Study. | J Am Geriatr Soc | 2017 |
| 29348926 | A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis. | Mult Scler J Exp Transl Clin | 2017 |
| 28623677 | Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study. | Alzheimers Dement | 2017 |
| 26715391 | The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. | CNS Drugs | 2016 |
| 26602628 | Importance of home study visit capacity in dementia studies. | Alzheimers Dement | 2016 |
| 26564998 | A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. | Mult Scler | 2016 |
| 25033130 | Characterization of dementia and Alzheimer's disease in an older population: updated incidence and life expectancy with and without dementia. | Am J Public Health | 2015 |